218 related articles for article (PubMed ID: 25934525)
1. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes.
Kato H; Nagai Y; Ohta A; Tenjin A; Nakamura Y; Tsukiyama H; Sasaki Y; Fukuda H; Ohshige T; Terashima Y; Sada Y; Kondo A; Sasaoka T; Tanaka Y
Diabetes Res Clin Pract; 2015 Jul; 109(1):199-205. PubMed ID: 25934525
[TBL] [Abstract][Full Text] [Related]
2. Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease.
Wang X; Zhao B; Sun H; You H; Qu S
Front Endocrinol (Lausanne); 2022; 13():866189. PubMed ID: 36072931
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study.
Hiruma S; Shigiyama F; Kumashiro N
Diabetes Obes Metab; 2023 Jun; 25(6):1576-1588. PubMed ID: 36749298
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus.
Hattori A; Takemoto M; Tokuyama H; Koshizaka M; Yokote K
Diabetes Res Clin Pract; 2017 Apr; 126():138-143. PubMed ID: 28237860
[TBL] [Abstract][Full Text] [Related]
6. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.
Cuthbertson DJ; Irwin A; Gardner CJ; Daousi C; Purewal T; Furlong N; Goenka N; Thomas EL; Adams VL; Pushpakom SP; Pirmohamed M; Kemp GJ
PLoS One; 2012; 7(12):e50117. PubMed ID: 23236362
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1).
Nomoto H; Miyoshi H; Furumoto T; Oba K; Tsutsui H; Inoue A; Atsumi T; Manda N; Kurihara Y; Aoki S;
PLoS One; 2016; 11(10):e0164255. PubMed ID: 27711199
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes.
Aso Y; Fukushima M; Sagara M; Jojima T; Iijima T; Suzuki K; Momobayashi A; Kasai K; Inukai T
Diabetes Res Clin Pract; 2015 Dec; 110(3):250-6. PubMed ID: 26508675
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
10. Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study.
Sakura H; Hashimoto N; Sasamoto K; Ohashi H; Hasumi S; Ujihara N; Kasahara T; Tomonaga O; Nunome H; Honda M; Iwamoto Y;
BMC Endocr Disord; 2016 Dec; 16(1):70. PubMed ID: 27905912
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin improves plasma apolipoprotein profile in type 2 diabetes: A randomized clinical trial of sitagliptin effect on lipid and glucose metabolism (SLIM) study.
Tanimura-Inagaki K; Nagao M; Harada T; Sugihara H; Moritani S; Sasaki J; Kono S; Oikawa S;
Diabetes Res Clin Pract; 2020 Apr; 162():108119. PubMed ID: 32194219
[TBL] [Abstract][Full Text] [Related]
12. Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study.
Goldshtein I; Karasik A; Melzer-Cohen C; Engel SS; Yu S; Sharon O; Brodovicz K; Gadir N; Katzeff HL; Radican L; Chodick G; Shalev V; Tunceli K
J Diabetes Complications; 2016; 30(7):1354-9. PubMed ID: 27320183
[TBL] [Abstract][Full Text] [Related]
13. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.
Dutour A; Abdesselam I; Ancel P; Kober F; Mrad G; Darmon P; Ronsin O; Pradel V; Lesavre N; Martin JC; Jacquier A; Lefur Y; Bernard M; Gaborit B
Diabetes Obes Metab; 2016 Sep; 18(9):882-91. PubMed ID: 27106272
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of initial treatment with glimpeiride versus sitagliptin in type 2 diabetes].
Tamez-Pérez HE;
Rev Med Inst Mex Seguro Soc; 2015; 53(2):142-8. PubMed ID: 25760742
[TBL] [Abstract][Full Text] [Related]
15. Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial.
Nahon KJ; Doornink F; Straat ME; Botani K; Martinez-Tellez B; Abreu-Vieira G; van Klinken JB; Voortman GJ; Friesema ECH; Ruiz JR; van Velden FHP; de Geus-Oei LF; Smit F; Pereira Arias-Bouda LM; Berbée JFP; Jazet IM; Boon MR; Rensen PCN
Diabetologia; 2018 Nov; 61(11):2386-2397. PubMed ID: 30145664
[TBL] [Abstract][Full Text] [Related]
16. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
Ohta A; Kato H; Ishii S; Sasaki Y; Nakamura Y; Nakagawa T; Nagai Y; Tanaka Y
Expert Opin Pharmacother; 2017 Oct; 18(14):1433-1438. PubMed ID: 28770629
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers.
Fukui K; Kawahito H; Wakana N; Kikai M; Terada K; Yamamoto K; Irie D; Kato T; Miyagawa S; Yamada H
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1001-9. PubMed ID: 26195265
[TBL] [Abstract][Full Text] [Related]
18. Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".
Mikada A; Narita T; Yokoyama H; Yamashita R; Horikawa Y; Tsukiyama K; Yamada Y
Diabetes Res Clin Pract; 2014 Dec; 106(3):538-47. PubMed ID: 25451890
[TBL] [Abstract][Full Text] [Related]
19. Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes.
Ishii S; Nagai Y; Kato H; Fukuda H; Tanaka Y
J Clin Med Res; 2020 Feb; 12(2):122-126. PubMed ID: 32095182
[TBL] [Abstract][Full Text] [Related]
20. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
